Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 398,700 shares, a decline of 17.2% from the January 31st total of 481,400 shares. Based on an average trading volume of 669,500 shares, the short-interest ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MIST. Toronto Dominion Bank purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at $1,770,000. Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the fourth quarter worth $729,000. Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $170,000. XTX Topco Ltd purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $80,000. Finally, BML Capital Management LLC increased its stake in shares of Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after acquiring an additional 33,196 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Up 20.7 %

Shares of MIST stock traded up $0.34 during mid-day trading on Wednesday, reaching $1.98. The stock had a trading volume of 2,219,210 shares, compared to its average volume of 894,526. The stock’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $1.77. The firm has a market capitalization of $105.59 million, a PE ratio of -2.44 and a beta of 1.80. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.